Latest Conference Articles

Preoperative radiation and pembrolizumab improved T-cell infiltration in patients with higher-risk, HR-positive, HER2-negative, early-stage breast cancer.

Phase 2 data demonstrated similar pharmacokinetic profiles between subcutaneous azacitidine and an oral combination of azacitidine and cedazuridine.

The use of sacituzumab govitecan to treat HR+/HER2– metastatic breast cancer did not reach its primary end point of progression-free survival.

Patients with relapsed/refractory large B-cell lymphoma treated with glofitamab or epcoritamab experienced early disease progression.

Six-month complete response with frontline axicabtagene ciloleucel predicts long-term survival in patients with high-risk large B-cell lymphoma.

Dexamethasone reduced the severity of ICANS but did not impact the rates of ICANS or CRS in patients with LBCL receiving axi-cel.

Subcutaneous bispecific antibody cevostamab demonstrated early efficacy and safety in patients with relapsed or refractory multiple myeloma.

Pirtobrutinib demonstrated noninferior response rates to ibrutinib and showed a trend toward survival benefit in patients with CLL/SLL.

Patients with AML receiving azacitidine and venetoclax had significantly higher quality of life than those receiving intensive induction chemotherapy.

The addition of epcoritamab to R2 significantly reduced the risk of death or disease progression in patients with relapsed/refractory follicular lymphoma.

Older patients with newly diagnosed diffuse large B-cell lymphoma receiving epcoritamab plus R-mini-CHOP achieved deep responses with manageable safety.

KRd demonstrated higher PFS, deeper response, and greater MRD negativity compared with VRd in newly diagnosed multiple myeloma.

The combination of odronextamab with CHOP chemotherapy showed early efficacy in patients with untreated diffuse large B-cell lymphoma.

Nearly one-third of families of children with acute lymphoblastic leukemia developed “catastrophic” financial toxicity during the patient’s treatment.

Higher LDH levels were linked with poorer survival outcomes in patients with relapsed and refractory multiple myeloma who received elranatamab.

The primary end point of EFS was met in patients given conditioning without TBI, along with allogeneic HCT in a subset of patients with B-ALL.

Fixed-duration venetoclax combined with obinutuzumab or ibrutinib produced noninferior PFS compared with continuous ibrutinib monotherapy.

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

Pembrolizumab plus paclitaxel with or without bevacizumab boosted survival in patients with platinum-resistant, recurrent ovarian cancer.

The addition of atezolizumab to BCG did not yield improved EFS compared with BCG alone in patients with high-risk non–muscle-invasive bladder cancer.

Nivolumab displayed significant RFS benefit compared with ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.

Here are 5 presentations that oncology APPs should know about, from patient management to practice management.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, explains that later cytopenias should be monitored in patients undergoing CAR T-cell therapy.

Durvalumab plus FLOT chemotherapy improved overall survival in resectable gastric or gastroesophageal junction cancer, per phase 3 MATTERHORN data.

An oncology APP-led quality assurance committee identified key safety events across disciplines and specialties.

The frontline addition of cancer vaccine IO102-IO103 to pembrolizumab demonstrated an increase in PFS in patients with advanced melanoma.

Daniel Glidden, MS, PA-C, discusses key data oncology APPs should be aware of and how to start incorporating exercise in cancer care.

T-DXd plus pertuzumab improved PFS and DOR across HER2+ breast cancer subgroups, regardless of prior therapy or PIK3CA mutation status.